| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Guardant Health Inc (NASDAQ: GH)
GH Technical Analysis
5
| As on 9th Jun 2023 GH STOCK Price closed @ 32.86 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 57.35 & Strong Sell for SHORT-TERM with Stoploss of 77.76 we also expect STOCK to react on Following IMPORTANT LEVELS. |
GHSTOCK Price
| Open | 32.80 | Change | Price | % |
| High | 33.17 | 1 Day | 0.27 | 0.83 |
| Low | 32.37 | 1 Week | 4.78 | 17.02 |
| Close | 32.86 | 1 Month | 11.41 | 53.19 |
| Volume | 980985 | 1 Year | -70.24 | -68.13 |
| 52 Week High 103.10 | 52 Week Low 20.94 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| GH Daily Charts |
GH Intraday Charts |
Whats New @ Bazaartrend |
GH Free Analysis |
|
|
GH Important Levels Intraday
| RESISTANCE | 34.40 |
| RESISTANCE | 33.91 |
| RESISTANCE | 33.60 |
| RESISTANCE | 33.30 |
| SUPPORT | 32.42 |
| SUPPORT | 32.12 |
| SUPPORT | 31.81 |
| SUPPORT | 31.32 |
GH Forecast May 2024
| 4th UP Forecast | 110.77 |
| 3rd UP Forecast | 85.78 |
| 2nd UP Forecast | 70.34 |
| 1st UP Forecast | 54.89 |
| 1st DOWN Forecast | 10.83 |
| 2nd DOWN Forecast | -4.62 |
| 3rd DOWN Forecast | -20.06 |
| 4th DOWN Forecast | -45.05 |
GH Weekly Forecast
| 4th UP Forecast | 47.72 |
| 3rd UP Forecast | 42.95 |
| 2nd UP Forecast | 40.01 |
| 1st UP Forecast | 37.06 |
| 1st DOWN Forecast | 28.66 |
| 2nd DOWN Forecast | 25.71 |
| 3rd DOWN Forecast | 22.77 |
| 4th DOWN Forecast | 18.00 |
GH Forecast2024
| 4th UP Forecast | 191.82 |
| 3rd UP Forecast | 140.84 |
| 2nd UP Forecast | 109.33 |
| 1st UP Forecast | 77.82 |
| 1st DOWN Forecast | -12.1 |
| 2nd DOWN Forecast | -43.61 |
| 3rd DOWN Forecast | -75.12 |
| 4th DOWN Forecast | -126.1 |
Guardant Health Inc ( NASDAQ USA Symbol : GH )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
GH Business Profile
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing tests from its LUNAR program for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; LUNAR-2 test for the early detection of cancer in asymptomatic individuals eligible for cancer screening; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for residual disease and recurrence monitoring; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical trial referral, and liquid biopsy testing development and support services to biopharmaceutical companies and medical institutions. Daiichi Sankyo has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California. Address: 505 Penobscot Drive, Redwood City, CA, United States, 94063
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service